Health Care & Life Sciences » Pharmaceuticals | Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries Ltd. | Income Statement

Fiscal year is April-March. All values USD Thousands.
2014
2015
2016
2017
2018
2019
Sales/Revenue
759,285.00
862,944.00
950,751.00
879,387.00
661,913.00
669,893
Cost of Goods Sold (COGS) incl. D&A
179,279.00
186,359.00
169,743.00
207,860.00
198,405.00
224,169
Gross Income
580,006.00
676,585.00
781,008.00
671,527.00
463,508.00
445,724
SG&A Expense
147,163.00
153,154.00
163,525.00
156,300.00
158,614.00
153,209
EBIT
432,843.00
523,431.00
617,483.00
515,227.00
304,894.00
292,515
Unusual Expense
2,590.00
4,200.00
3,015.00
276.00
1,884.00
3,678
Non Operating Income/Expense
8,487.00
44,372.00
9,748.00
31,248.00
30,880.00
26,863
Interest Expense
1,516.00
928.00
473.00
-
-
-
Pretax Income
443,907.00
581,680.00
636,820.00
560,798.00
292,368.00
356,854
Income Tax
82,729.00
96,059.00
95,313.00
103,780.00
81,954.00
74,732
Consolidated Net Income
361,178.00
485,621.00
541,507.00
457,018.00
210,414.00
282,122
Net Income
360,706.00
485,044.00
541,168.00
456,708.00
211,485.00
281,777
Net Income After Extraordinaries
361,025.00
485,831.00
541,404.00
457,060.00
211,820.00
281,777
Net Income Available to Common
360,387.00
484,257.00
540,932.00
456,356.00
211,150.00
281,777
EPS (Basic)
8.14
11.31
12.63
11.05
5.26
7.23
Basic Shares Outstanding
-
-
-
-
40,155.10
38,990.10
EPS (Diluted)
-
-
-
-
5.26
7.23
Diluted Shares Outstanding
-
-
-
-
40,155.10
38,990.10
EBITDA
449,410.00
539,229.00
632,331.00
530,056.00
321,390.00
311,112
Non-Operating Interest Income
6,683.00
10,605.00
13,077.00
14,599.00
20,238.00
33,798
Minority Interest Expense
472.00
577.00
339.00
310.00
1,071.00
345

About Taro Pharmaceutical Industries

View Profile
Address
14 Hakitor Street
Haifa Bay HA 26247
Israel
Employees -
Website http://www.taro.com
Updated 07/08/2019
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing, and marketing of prescribed and over-the-counter pharmaceutical products in the U. S. , Canada, and Israel.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.